Trailblazing the path to transcription factors by intervening at a previously hidden region we have identified as the ‘switch site.’



To date, the collective research on transcription factors has been elusive to drug discovery. However, Flare Therapeutics has now reached a moment of light – with the prospect of forever changing the trajectory of how we treat disease.



Flare Therapeutics’ pipeline is Initially focused on precision oncology.

Our small molecules are designed to regain transcriptional control that is hijacked by cancer.




Intensity, empathy, determination, and brilliance. The Flare Therapeutics team is a living, growing, thriving organization of talented people and bright minds. We are always looking for new sparks to flame our collective fire. Learn more about our culture and join us!

  Join Us

Flare Therapeutics Presents FX-909 Phase 1 Dose Escalation and Expansion Clinical Trial Design at the 2024 ASCO Genitourinary Cancers Symposium
--First-in-human trial evaluating safety, tolerability, and clinical activity of FX-909 in patients with advanced solid malignancies including advanced urothelial carcinoma--

  Read full story


This links to an external website.